
|Articles|September 1, 2006
Taxane-refractory PCa: Regimens offer modest results
Atlanta-A trial of drug regimens in hormone-refractory prostate cancer came up with only modest results, but it did take an important first step: It is one of the first prospective trials conducted in taxane-refractory disease.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
4
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
5